Danco Laboratories, the pharmaceutical company behind the abortion pill Mifepristone, filed an emergency motion with the Supreme Court on Saturday asking the justices to halt a federal appeals court ruling that bars doctors from prescribing the drug through telehealth or dispensing it by mail. The move came just one day after a three-judge panel on the 5th U.S. Circuit Court of Appeals sided with Louisiana and imposed a temporary nationwide injunction reinstating a 2021 requirement that the pill be prescribed and dispensed in person.
The filing marks the latest escalation in a legal fight that has bounced between federal courts for years, and it lands squarely on the Supreme Court's doorstep at a moment when the justices are already navigating internal tensions over the shadow docket and high-stakes emergency petitions.
At its core, the case pits a state's authority to regulate abortion within its borders against a federal agency's decision to loosen drug-safety rules, a tension the Dobbs decision was supposed to resolve by returning abortion policy to the states. Louisiana says the FDA's relaxed dispensing rules made it easier for abortion pills to arrive by mail in states where the procedure is mostly banned. Danco says the appeals court's order creates chaos.
On Friday, the 5th Circuit panel issued a temporary nationwide injunction in a case Louisiana brought against the Food and Drug Administration. The ruling reinstates the in-person prescribing and dispensing requirement that existed before the Biden-era FDA permanently removed it. That removal happened roughly eighteen months before the Supreme Court's 2024 decision on Mifepristone, as The Hill reported.
Danco's May 2 emergency motion asks the justices for an "immediate administrative stay" of the 5th Circuit's order while the Court considers a broader appeal. The Delaware-based company framed the ruling as disruptive and without precedent.
Lawyers for Danco stated in the filing:
"The panel's ruling injects immediate confusion and upheaval into highly time-sensitive medical decisions, and it forces Danco, FDA, certified Mifeprex providers, patients, and pharmacies all to guess at what is allowed and what is not."
They also called the 5th Circuit's order "unprecedented" and "extremely disruptive," warning of "regulatory whiplash" for providers and pharmacies nationwide.
Mifepristone is one of two drugs commonly used in medication abortions. The FDA first approved it in 2000. For more than two decades, federal rules required the pill to be prescribed and dispensed in person, a safeguard that reflected the drug's classification under the agency's risk-management framework.
Under former President Biden, the FDA permanently removed that in-person requirement, opening the door to telehealth prescriptions and mail delivery. The timing matters. That regulatory change came before the Supreme Court weighed in on the drug's availability in 2024.
When the justices did take up the question, they unanimously rejected a challenge from anti-abortion doctors, but on narrow procedural grounds. The Court found those challengers lacked legal standing. It did not rule on the merits of the FDA's loosened dispensing rules.
That left the door open for a state with direct standing to bring its own challenge. Louisiana walked through it. The state's officials argued that the Biden-era FDA rules made it easier for abortion pills to be mailed into states where abortion is mostly banned, effectively undermining the authority the Dobbs decision returned to state legislatures in 2022.
Louisiana has gone further than litigation. The state has attempted to prosecute out-of-state doctors for providing abortion drugs via mail to residents within its borders, an assertion of state sovereignty that abortion-rights advocates have fiercely opposed.
The political reaction followed a well-worn script. Sen. Patty Murray (D-Wash.) took to social media almost immediately, writing that "The Fifth Circuit just told millions of women that three judges know better than the FDA, their doctors, and 25 years of evidence. They don't."
She added: "I have no intention of letting this stand."
Murray's response fits a pattern visible across recent Supreme Court and federal court battles. When rulings go against progressive priorities, Democratic leaders frame the judiciary itself as the problem, as seen when Barack Obama attacked the Supreme Court after a ruling that voided a race-based redistricting map. The reflex is always the same: question the legitimacy of the court rather than engage the legal reasoning.
But Murray's framing sidesteps the central issue. The 5th Circuit panel did not question whether Mifepristone should exist on the market. It addressed whether the FDA's decision to strip away in-person dispensing safeguards, and allow the drug to flow through the mail into states that restrict abortion, exceeded the agency's authority or undermined state law. Those are legitimate legal questions, not an attack on medicine.
The broader pattern of Democrats scrambling after unfavorable court decisions has become a recurring feature of the post-Dobbs landscape. Rather than accept that the constitutional framework now gives states primary authority over abortion regulation, progressive leaders and allied institutions keep running to federal courts, or attacking them when the answers come back wrong.
The justices must now decide whether to grant Danco's request for an administrative stay. If they do, the 5th Circuit's injunction would be paused, and the pre-Friday status quo, telehealth prescriptions and mail delivery, would resume while the appeal proceeds. If they decline, the in-person requirement snaps back into effect nationwide.
Danco's lawyers framed the stakes in urgent terms:
"The Fifth Circuit's unprecedented order forces patients, providers, and pharmacies into immediate uncertainty, with no transition period and no practical guidance."
That language is designed to push the Court toward intervention. But the other side of the ledger deserves equal weight. Louisiana and states with similar abortion restrictions have a straightforward argument: the FDA's rule change effectively nullified state abortion laws by enabling a mail-order pipeline that bypasses every safeguard those states enacted after Dobbs. If the federal regulatory apparatus can override state law simply by loosening dispensing rules for a single drug, the promise of Dobbs, that states would decide, rings hollow.
Several open questions remain. The names of the three judges on the 5th Circuit panel have not been identified in available reporting. The precise scope and duration of the temporary nationwide injunction are unclear. And the full case name and docket number for Danco's emergency motion have not been disclosed.
The Supreme Court has handled Mifepristone-related disputes before, and the justices are no strangers to emergency petitions that arrive over weekends. How quickly they act, and whether they treat this as a routine stay request or a signal of how they view the merits, will shape the legal and political landscape around abortion access for months to come. The Court's recent willingness to engage with landmark cases involving Louisiana suggests the justices are not shy about wading into politically charged disputes when the legal questions are ripe.
Danco's filing leans hard on disruption, "confusion," "upheaval," "regulatory whiplash." Those are real concerns for any regulated industry facing a sudden rule change. But the company's argument conveniently avoids a harder question: Should a federal agency be able to strip away drug-safety requirements in a way that functionally overrides the abortion laws of sovereign states?
The FDA approved Mifepristone in 2000 with an in-person dispensing requirement. That requirement stood for more than two decades. The Biden administration removed it. The 5th Circuit reinstated it. Each step in that chain reflects a policy choice, and the states that restrict abortion have every right to argue that the loosened federal rules undercut their democratically enacted laws.
The Dobbs decision told Americans that abortion policy belongs to the states. If a federal agency can undo that promise with a regulatory pen stroke, then the promise was never real to begin with. That is the question the Supreme Court will have to face, no matter how loudly Danco or Senator Murray complain about the judges who raised it.
